Perez Nicolas, Karumuthil-Melethil Subha, Li Ruobing, Prabhakar Bellur S, Holterman Mark J, Vasu Chenthamarakshan
Department of Surgery, College of Medicine, University of Illinois, Chicago, IL 60612, USA.
J Immunol. 2008 May 15;180(10):6566-76. doi: 10.4049/jimmunol.180.10.6566.
Costimulatory ligands CD80 and CD86 have different binding preferences and affinities to their receptors, CD28 and CTLA-4. Earlier, we demonstrated that CD80 binds to CTLA-4 with higher affinity and has a role in suppressing T cell response. The current study demonstrates that not only did blockade of CD86 upon Ag presentation by bone marrow-derived dendritic cells (DC) to OVA-specific T cells result in induction of hyporesponsive T cells but also that these T cells could suppress the proliferative response of effector T cells. These T cells showed TGF-beta1 on their surface and secreted TGF-beta1 and IL-10 upon restimulation. Although blockade of CTLA-4 and neutralization of IL-10 profoundly inhibited the induction of these TGF-beta1(+) T cells, their ability to suppress the effector T cell proliferation was abrogated by neutralization of TGF-beta1 alone. Induction of TGF-beta1(+) and IL-10(+) T cells was found to be independent of natural CD4(+)CD25(+) regulatory T cells, demonstrating that preferential ligation of CTLA-4 by CD80 induced IL-10 production by effector T cells, which in turn promoted the secretion of TGF-beta1. Treatment of prediabetic NOD mice with islet beta cell Ag-pulsed CD86(-/-) DCs, but not CD80(-/-) DCs, resulted in the induction of TGF-beta1- and IL-10-producing cells, significant suppression of insulitis, and delay of the onset of hyperglycemia. These observations demonstrate not only that CD80 preferentially binds to CTLA-4 but also that interaction during Ag presentation can result in IL-10-dependent TGF-beta1(+) regulatory T cell induction, reinstating the potential of approaches to preferentially engage CTLA-4 through CD80 during self-Ag presentation in suppressing autoimmunity.
共刺激配体CD80和CD86对其受体CD28和CTLA-4具有不同的结合偏好和亲和力。此前,我们证明CD80以更高的亲和力与CTLA-4结合,并在抑制T细胞反应中发挥作用。当前研究表明,骨髓来源的树突状细胞(DC)向卵清蛋白特异性T细胞呈递抗原时阻断CD86,不仅会诱导低反应性T细胞,而且这些T细胞能够抑制效应T细胞的增殖反应。这些T细胞表面显示转化生长因子-β1(TGF-β1),再次刺激时会分泌TGF-β1和白细胞介素-10(IL-10)。虽然阻断CTLA-4和中和IL-10可显著抑制这些TGF-β1(+) T细胞的诱导,但仅中和TGF-β1就可消除它们抑制效应T细胞增殖的能力。发现TGF-β1(+)和IL-10(+) T细胞的诱导独立于天然CD4(+)CD25(+)调节性T细胞,这表明CD80对CTLA-4的优先结合诱导效应T细胞产生IL-10,进而促进TGF-β1的分泌。用胰岛β细胞抗原脉冲处理的CD86(-/-) DC而非CD80(-/-) DC对糖尿病前期非肥胖糖尿病(NOD)小鼠进行治疗,可诱导产生TGF-β1和IL-10的细胞,显著抑制胰岛炎,并延缓高血糖症的发作。这些观察结果不仅表明CD80优先与CTLA-4结合,而且抗原呈递过程中的相互作用可导致IL-10依赖性TGF-β1(+)调节性T细胞的诱导,恢复了在自身抗原呈递过程中通过CD80优先结合CTLA-4来抑制自身免疫的方法的潜力。